Phagos valuation, funding and investors
Phagos works in phage-based drug development, based in Suresnes, France. Founded in 2021, it has about 78 employees.
- Last round
- Series A · $29.0M · Oct 2025
- Valuation at last round
- $148M · implied
- Headcount
- 78 · growing
- Grade
- C
- Founded
- 2021
Phagos valuation today
VCMC values Phagos at $295M today, with a range of $108M to $449M and a grade of C. The valuation starts from its last funding round, a Series A round in Oct 2025.
Valuation by date (73 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2021 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $10.8M | $3.93M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.1M | $4.03M – $30.4M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.2M | $4.07M – $30.7M | $12.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $11.3M | $4.10M – $31.0M | $12.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $11.4M | $4.14M – $31.2M | $12.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $11.5M | $4.18M – $31.5M | $12.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $11.6M | $4.22M – $31.8M | $12.7M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $11.7M | $4.25M – $32.1M | $12.8M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $11.8M | $4.29M – $32.4M | $12.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $11.9M | $4.33M – $32.7M | $13.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $9.94M | $3.62M – $27.3M | $10.9M (+9%) | before first round | 5 | unknown | D | 0% |
| 1 Mar 2022 | $10.0M | $3.64M – $27.5M | $10.9M (+9%) | before first round | 5 | unknown | D | 0% |
| 1 Apr 2022 | $10.1M | $3.67M – $27.7M | $11.0M (+9%) | before first round | 5 | unknown | D | 0% |
| 1 May 2022 | $10.2M | $3.70M – $27.9M | $11.1M (+9%) | before first round | 5 | unknown | D | 0% |
| 1 Jun 2022 | $10.2M | $3.73M – $28.1M | $11.2M (+9%) | before first round | 5 | unknown | D | 0% |
| 1 Jul 2022 | $7.65M | $5.02M – $23.3M | $15.3M (+100%) | after a round | 5 | unknown | C | 0% |
| 2 Jul 2022 | $7.66M | $5.02M – $23.3M | $15.3M (+100%) | after a round | 5 | unknown | C | 0% |
| 1 Aug 2022 | $8.11M | $5.02M – $23.3M | $15.3M (+89%) | after a round | 5 | unknown | C | 0% |
| 1 Sep 2022 | $8.60M | $5.02M – $23.3M | $15.3M (+78%) | after a round | 5 | unknown | C | 0% |
| 1 Oct 2022 | $9.10M | $5.02M – $23.3M | $15.3M (+68%) | after a round | 5 | unknown | C | 0% |
| 1 Nov 2022 | $9.66M | $5.02M – $23.3M | $15.3M (+58%) | after a round | 5 | unknown | C | 0% |
| 1 Dec 2022 | $10.2M | $5.02M – $23.3M | $15.3M (+50%) | after a round | 5 | unknown | C | 0% |
| 1 Jan 2023 | $11.6M | $5.72M – $26.5M | $17.4M (+50%) | after a round | 9 | unknown | C | 0% |
| 1 Feb 2023 | $12.4M | $5.72M – $26.5M | $17.4M (+40%) | after a round | 9 | unknown | C | 0% |
| 1 Mar 2023 | $13.2M | $5.72M – $26.5M | $17.4M (+32%) | after a round | 9 | unknown | C | 0% |
| 1 Apr 2023 | $14.2M | $5.72M – $26.5M | $17.4M (+23%) | after a round | 9 | unknown | C | 0% |
| 1 May 2023 | $15.2M | $5.72M – $26.5M | $17.4M (+15%) | after a round | 9 | unknown | C | 0% |
| 1 Jun 2023 | $16.3M | $5.72M – $26.5M | $17.4M (+7%) | after a round | 9 | unknown | C | 0% |
| 1 Jul 2023 | $17.4M | $5.72M – $26.5M | $17.4M (0%) | after a round | 9 | unknown | C | 0% |
| 1 Aug 2023 | $17.4M | $5.44M – $26.5M | $17.4M (0%) | after a round | 9 | unknown | C | 0% |
| 1 Sep 2023 | $17.4M | $5.17M – $26.5M | $17.4M (0%) | after a round | 9 | unknown | C | 0% |
| 1 Oct 2023 | $19.5M | $6.48M – $29.6M | $19.5M (0%) | after a round | 15 | growing | C | 0% |
| 1 Nov 2023 | $19.5M | $6.51M – $29.6M | $19.5M (0%) | after a round | 15 | growing | C | 0% |
| 1 Dec 2023 | $19.5M | $6.54M – $29.6M | $19.5M (0%) | after a round | 15 | growing | C | 0% |
| 1 Jan 2024 | $19.5M | $6.56M – $29.6M | $19.5M (0%) | after a round | 15 | growing | C | 0% |
| 1 Feb 2024 | $19.5M | $6.59M – $29.6M | $19.5M (0%) | after a round | 15 | growing | C | 0% |
| 1 Mar 2024 | $20.7M | $7.05M – $31.6M | $20.7M (0%) | after a round | 20 | growing | C | 0% |
| 1 Apr 2024 | $20.7M | $7.08M – $31.6M | $20.7M (0%) | after a round | 20 | growing | C | 0% |
| 1 May 2024 | $20.7M | $7.11M – $31.6M | $20.7M (0%) | after a round | 20 | growing | C | 0% |
| 1 Jun 2024 | $20.7M | $7.15M – $31.6M | $20.7M (0%) | after a round | 20 | growing | C | 0% |
| 1 Jul 2024 | $20.7M | $6.44M – $31.6M | $20.7M (0%) | after a round | 20 | growing | C | 0% |
| 1 Aug 2024 | $20.7M | $3.87M – $31.6M | $20.7M (0%) | after a round | 20 | up | D | 0% |
| 1 Sep 2024 | $20.7M | $3.71M – $31.6M | $20.7M (0%) | after a round | 20 | up | D | 0% |
| 1 Oct 2024 | $20.7M | $3.55M – $31.6M | $20.7M (0%) | after a round | 20 | up | D | 0% |
| 1 Nov 2024 | $20.7M | $3.40M – $31.6M | $20.7M (0%) | after a round | 20 | up | D | 0% |
| 1 Dec 2024 | $20.7M | $3.26M – $31.6M | $20.6M (0%) | after a round | 20 | up | D | 0% |
| 1 Jan 2025 | $20.7M | $3.12M – $31.6M | $20.6M (-1%) | after a round | 20 | up | D | 0% |
| 1 Feb 2025 | $20.7M | $2.98M – $31.6M | $20.6M (-1%) | after a round | 20 | up | D | 0% |
| 1 Mar 2025 | $20.7M | $2.87M – $31.6M | $20.6M (-1%) | after a round | 20 | up | D | 0% |
| 1 Apr 2025 | $20.7M | $2.74M – $31.6M | $20.6M (-1%) | after a round | 20 | up | D | 0% |
| 1 May 2025 | $20.7M | $2.27M – $31.6M | $19.1M (-8%) | after a round | 20 | flat | D | 0% |
| 1 Jun 2025 | $20.7M | $2.16M – $31.6M | $18.9M (-9%) | after a round | 20 | flat | D | 0% |
| 1 Jul 2025 | $20.7M | $2.05M – $31.6M | $18.8M (-10%) | after a round | 20 | flat | D | 0% |
| 1 Aug 2025 | $24.5M | $7.12M – $37.4M | $24.5M (0%) | after a round | 43 | growing | C | 0% |
| 1 Sep 2025 | $24.5M | $6.97M – $37.4M | $24.5M (0%) | after a round | 43 | growing | C | 0% |
| 1 Oct 2025 | $24.5M | $6.82M – $37.4M | $24.5M (0%) | after a round | 43 | growing | C | 0% |
| 9 Oct 2025 | $148M | $97.1M – $405M | $266M (+80%) | after a round | 43 | growing | C | 0% |
| 1 Nov 2025 | $154M | $97.1M – $405M | $266M (+73%) | after a round | 49 | growing | C | 0% |
| 1 Dec 2025 | $161M | $97.1M – $405M | $266M (+65%) | after a round | 49 | growing | C | 0% |
| 1 Jan 2026 | $170M | $98.0M – $409M | $268M (+58%) | after a round | 51 | growing | C | 0% |
| 1 Feb 2026 | $179M | $98.0M – $409M | $268M (+50%) | after a round | 51 | growing | C | 0% |
| 1 Mar 2026 | $187M | $98.0M – $409M | $268M (+44%) | after a round | 51 | growing | C | 0% |
| 1 Apr 2026 | $197M | $98.0M – $409M | $268M (+36%) | after a round | 51 | growing | C | 0% |
| 1 May 2026 | $216M | $106M – $441M | $290M (+34%) | after a round | 72 | growing | C | 0% |
| 1 Jun 2026 | $228M | $106M – $441M | $290M (+27%) | after a round | 72 | growing | C | 0% |
| 1 Jul 2026 | $241M | $106M – $441M | $290M (+20%) | after a round | 72 | growing | C | 0% |
| 1 Aug 2026 | $256M | $106M – $442M | $290M (+13%) | after a round | 73 | growing | C | 0% |
| 1 Sep 2026 | $271M | $106M – $442M | $290M (+7%) | after a round | 73 | growing | C | 0% |
| 1 Oct 2026 | $291M | $108M – $449M | $295M (+1%) | after a round | 78 | growing | C | 0% |
| 24 Oct 2026 | $295M | $108M – $449M | $295M (0%) | after a round | 78 | growing | C | 0% |
Key facts about Phagos
- Founded
- 2021
- Headquarters
- Suresnes, France
- Employees
- about 78 +59% in a year
- Total raised
- $31M
- Funding rounds
- 2
- Last round
- Series A Oct 2025
Phagos was founded in 2021 by Alexandros Pantalis, Andreas Tzoumas and Ioannis Tsanaktsidis.
Phagos funding history
Phagos has 2 funding rounds on record, from Jul 2022 to Oct 2025, $31M in total. None disclosed a valuation.
Series A 8 Oct 2025
Led by Capagro, Hoxton Ventures, CapHorn Invest, Demeter; with Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, Station F.
Sources: techfundingnews.com, phagos.com, phagos.com and 2 more
$29M
Seed 1 Jul 2022
With Bpifrance, Entrepreneurs First, AWS Startups, Agoranov, StartLife, AgFunder, Hoxton Ventures, Demeter Partners, Citizen Capital, Acurio Ventures.
$1.5M
Phagos investors
15 investors have backed Phagos; Hoxton Ventures, Capagro and CapHorn Invest and 1 more led at least one round.
- Hoxton Ventures lead, 2 rounds
- Demeter lead
- Acurio Ventures 2 rounds
- Citizen Capital 2 rounds
- Agoranov
- AWS Startups
- Bpifrance
- Demeter Partners
- StartLife
- Station F
What Phagos does
Phagos works in pharmaceutical products, with 9 recorded offerings and customers in healthcare, animal health and food and beverage.
Phagos is a French biotechnology company engaged in phage therapy, combining microbiology and artificial intelligence to develop personalized, scalable phage-based treatments for bacterial infections in animal health and human health. The company also operates as a developer of phage-based drugs for veterinary use and utilizes its Alphagos platform to design targeted treatments. Phagos serves clients across Europe, Asia, and the Americas.
Description from Veridion's company data.
Products and services
- Phage-Based Drug Development
- Personalized Phage Therapy Design
- AI-Driven Microbiome Analysis Services
- Veterinary Phage Therapy Services
- Human Health Phage Therapy Services
- Antibiotic Resistance Mitigation Solutions
- Food Safety Improvement Solutions
- Sustainable Antibiotic Alternative Solutions
- Global Phage Therapy Distribution
Markets
- Healthcare
- Animal Health
- Food and Beverage
Technology
- AI-Driven Phage Genome Analysis
- Phage Therapy
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 325414 Biological Product (except Diagnostic) Manufacturing 100% match
Questions about Phagos
What is Phagos worth?
Valuation $295M (range $108M to $449M), as of 24 Oct 2026.
Has Phagos raised money?
Phagos has 2 funding rounds on record, from Jul 2022 to Oct 2025, $31M in total. None disclosed a valuation.
Who has invested in Phagos?
Hoxton Ventures, Capagro, CapHorn Invest, Demeter, Acurio Ventures and Citizen Capital, and 9 more. Lead investors include Hoxton Ventures, Capagro, CapHorn Invest and Demeter.
How many people work at Phagos?
About 78, up 59% over the last year. Headcount grew from 5 in Feb 2022 to 78 in Sep 2026.
What does Phagos do?
Phagos works in pharmaceutical products, with 9 recorded offerings and customers in healthcare, animal health and food and beverage. Its main offerings are phage-based drug development, personalized phage therapy design and AI-Driven microbiome analysis services.
When was Phagos founded, and where is it based?
Phagos was founded in 2021 and is based in Suresnes, France. It has about 78 employees, up 59% over the last year.